Patents Assigned to Kyorin Pharmaceuticals Co., Ltd.
-
Patent number: 11952387Abstract: [Problem] To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. [Solution] Provided are a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof.Type: GrantFiled: August 20, 2019Date of Patent: April 9, 2024Assignee: KYORIN PHARMACEUTICAL CO., LTDInventors: Masahiko Kinebuchi, Takekazu Kondou, Koji Ochiai, Yosuke Nishigaya
-
Patent number: 11781181Abstract: The present invention provides a reciprocal-flow-type nucleic acid amplification device comprising: heaters capable of forming a denaturation temperature zone and an extension/annealing temperature zone; a fluorescence detector capable of detecting movement of a sample solution between the two temperature zones; a pair of liquid delivery mechanisms that allow the sample solution to move between the two temperature zones and that are configured to be open to atmospheric pressure when liquid delivery stops; a substrate on which the chip for nucleic acid amplification according to claim 2 can be placed; and a control mechanism that controls driving of each liquid delivery mechanism by receiving an electrical signal from the fluorescence detector relating to movement of the sample solution from the control mechanism; the device being capable of performing real-time PCR by measuring fluorescence intensity for each thermal cycle.Type: GrantFiled: February 5, 2020Date of Patent: October 10, 2023Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hidenori Nagai, Shunsuke Furutani, Yoshihisa Hagihara, Yusuke Fuchiwaki
-
Publication number: 20230302448Abstract: In a nucleic acid amplification chip, a filter is provided inside or outside a PCR reaction container with respect to a micro-flow channel. Here, the filter is fixed to the PCR reaction container via a fixing portion. In this case, since the fixing portion is formed, the reliability of fixing the filter to the PCR reaction container can be improved. For this reason, the leakage of an evaporated sample solution (aerosol) from a gap between the filter and the PCR reaction container can be suppressed. Further, since the fixing portion is formed, the leakage of the evaporated sample solution (aerosol) can be suppressed without increasing the thickness of the filter, so that the filter can be made thin. As a result, the overall thickness of the nucleic acid amplification chip can also be reduced, so that the degree of freedom in designing the nucleic acid amplification chip is improved.Type: ApplicationFiled: August 6, 2021Publication date: September 28, 2023Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Keisuke GOHDA, Kentaro UMEI
-
Publication number: 20230285977Abstract: A nucleic acid amplification device, on which a nucleic acid amplification chip is placed, includes: temperature regulation units forming a denaturation temperature zone and an extension and annealing temperature zone; liquid delivery mechanisms that equalize air pressures of an air suction portion and an air discharge portion when liquid delivery is stopped; a detection unit that detects a sample solution in the nucleic acid amplification chip; and a control unit that controls the liquid delivery mechanisms based on a detection result of the detection unit. The detection unit includes an infrared light source that emits an infrared ray, and an infrared detection element that detects the infrared ray.Type: ApplicationFiled: August 6, 2021Publication date: September 14, 2023Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventor: Keisuke GOHDA
-
Publication number: 20230082516Abstract: [Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: January 7, 2020Publication date: March 16, 2023Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Shigeki SETO, Hitomi YAMADA, Yoshifumi SAITO, Haruaki KURASAKI
-
Publication number: 20220347181Abstract: [Problem] To provide a novel therapeutic agent for nocturnal pollakiuria. [Solution] A therapeutic agent for nocturnal pollakiuria which contains, as an active ingredient, (6S)—N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide.Type: ApplicationFiled: May 31, 2022Publication date: November 3, 2022Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Katsuya SEGAWA, Takafumi KUROSE
-
Publication number: 20220332730Abstract: [Problem] To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. [Solution] Provided are a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof.Type: ApplicationFiled: August 20, 2019Publication date: October 20, 2022Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Masahiko KINEBUCHI, Takekazu KONDOU, Koji OCHIAI, Yosuke NISHIGAYA
-
Patent number: 11376253Abstract: [Problem] To provide a novel therapeutic agent for nocturnal pollakiuria. [Solution] A therapeutic agent for nocturnal pollakiuria which contains, as an active ingredient, (6S)—N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide.Type: GrantFiled: December 20, 2018Date of Patent: July 5, 2022Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Katsuya Segawa, Takafumi Kurose
-
Publication number: 20220145360Abstract: The invention provides a reciprocal-flow-type nucleic acid amplification method performing thermal cycling by reciprocating a sample liquid between a denaturation temperature zone and an elongation-annealing temperature zone with a connected microchannel including at least a curved channel corresponding to the denaturation temperature zone, a curved channel corresponding to the elongation-annealing temperature zone, a linear or curved intermediate channel that connects the aforementioned curved channels, and a connector to connect to a liquid delivery mechanism for enabling movement of the sample liquid.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hidenori NAGAI, Satoru IWANAMI
-
Patent number: 11326163Abstract: Disclosed is a phosphorylation inhibitor of SMAD2/3 protein or a therapeutic agent for fibrosis which contains as an active ingredient, a nucleic acid that suppresses NEK6 (NIMA-related serine/threonine kinase 6) gene expression.Type: GrantFiled: July 30, 2018Date of Patent: May 10, 2022Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kazuhisa Nakao, Junichi Ishiyama, Wataru Ichikawa, Atsushi Masui, Yunike Akasaka, Hidekazu Toyofuku, Aya Honda
-
Publication number: 20220088057Abstract: Disclosed is an antisense nucleic acid that suppresses NEK6 gene expression.Type: ApplicationFiled: January 25, 2019Publication date: March 24, 2022Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kazuhisa NAKAO, Junichi ISHIYAMA, Wataru ICHIKAWA, Atsushi MASUI, Yunike AKASAKA, Aya HONDA
-
Patent number: 11261155Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: May 21, 2020Date of Patent: March 1, 2022Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 11098347Abstract: The present invention provides a reciprocal-flow-type nucleic acid amplification device comprising: heaters capable of forming a denaturation temperature zone and an extension/annealing temperature zone; a fluorescence detector capable of detecting movement of a sample solution between the two temperature zones; a pair of liquid delivery mechanisms that allow the sample solution to move between the two temperature zones and that are configured to be open to atmospheric pressure when liquid delivery stops; a substrate on which the chip for nucleic acid amplification according to claim 2 can be placed; and a control mechanism that controls driving of each liquid delivery mechanism by receiving an electrical signal from the fluorescence detector relating to movement of the sample solution from the control mechanism; the device being capable of performing real-time PCR by measuring fluorescence intensity for each thermal cycle.Type: GrantFiled: July 7, 2015Date of Patent: August 24, 2021Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN Pharmaceutical Co., Ltd.Inventors: Hidenori Nagai, Shunsuke Furutani, Yoshihisa Hagihara, Yusuke Fuchiwaki
-
Publication number: 20210187510Abstract: A PCR vessel having: a substrate, a flow channel formed in the substrate, a pair of filters provided at both ends of the flow channel, a pair of air communication ports communicating with the flow channel through the filters, a thermal cycle region formed between the pair of filters in the flow channel, and a sample injection port through which a sample can be injected into the flow channel from above; wherein the sample injection port in the surface of the substrate has an area of 0.7 to 1.8 mm2.Type: ApplicationFiled: August 29, 2019Publication date: June 24, 2021Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hidenori NAGAI, Shunsuke FURUTANI, Hideyasu KUBO
-
Publication number: 20210137913Abstract: [Problem] The present invention pertains to a safer and more efficient therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess, the agent containing as an active ingredient 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 15, 2018Publication date: May 13, 2021Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Masaaki ODAJIMA, Sayoko TANIOKA, Takaaki SUNOUCHI, Asako TABUCHI
-
Publication number: 20210087556Abstract: Disclosed is a phosphorylation inhibitor of SMAD2/3 protein or a therapeutic agent for fibrosis which contains as an active ingredient, a nucleic acid that suppresses NEK6 (NIMA-related serine/threonine kinase 6) gene expression.Type: ApplicationFiled: July 30, 2018Publication date: March 25, 2021Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kazuhisa Nakao, Junichi Ishiyama, Wataru Ichikawa, Atsushi Masui, Yunike Akasaka, Hidekazu Toyofuku, Aya Honda
-
Publication number: 20210052572Abstract: [Problem] The present invention pertains to a safer and more effective respiratory infection treating agent. [Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 5, 2020Publication date: February 25, 2021Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kota KUME, Hisao YOSHIDA, Hirotaka ANDO, Yuta TANAKA
-
Patent number: 10918634Abstract: [Problem] The present invention pertains to a safer and more effective respiratory infection treating agent. [Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 13, 2018Date of Patent: February 16, 2021Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kota Kume, Hisao Yoshida, Hirotaka Ando, Yuta Tanaka
-
Publication number: 20210000831Abstract: [Problem] To provide a novel therapeutic agent for nocturnal pollakiuria. [Solution] A therapeutic agent for nocturnal pollakiuria which contains, as an active ingredient, (6S)—N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide.Type: ApplicationFiled: December 20, 2018Publication date: January 7, 2021Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Katsuya SEGAWA, Takafumi KUROSE
-
Patent number: 10858314Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: GrantFiled: May 26, 2016Date of Patent: December 8, 2020Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Hiroyuki Watanabe, Kiyoshi Fujii, Mitsuhito Shibasaki, Mikako Kawashima, Megumi Kamiya, Kohei Ohata